Raising Health
Harnessing Water Dynamics for Drug Design with Michael Crackower and Jason Burch
Aug 20, 2024
Michael Crackower, Chief Scientific Officer at Ventus Therapeutics, and PhD researcher Jason Burch dive into the future of drug discovery. They unveil the ReSOLVE platform, designed to quickly iterate small molecular compounds for therapeutic use. The duo discusses the importance of water dynamics in protein interactions, machine learning's role in drug design, and their strides in targeting NLRP3 for neurodegenerative diseases. With groundbreaking data and a push to enter clinical trials, they highlight the rapid progress made from concept to investigational new drug.
37:24
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Ventus Therapeutics' ReSOLVE platform revolutionizes drug design by treating water as a dynamic entity for better molecular interactions.
- The company's strategic focus on the innate immune system opens doors to innovative therapies for aging-related and mitochondrial dysfunction diseases.
Deep dives
Innovations in Drug Discovery
Ventus Therapeutics focuses on leveraging the Resolve platform to transform drug discovery processes, particularly concerning small molecules. This platform enables more precise design and iteration of small molecular compounds for therapeutic use, aiming to increase the efficiency and speed of getting drugs into clinical testing. For instance, they discussed transitioning from initial drug candidates to Investigational New Drug (IND) status in record time, having achieved three such transitions within a single year, which is rare in the pharmaceutical industry. This approach marks a significant advancement from traditional methods, highlighting the potential of small molecules in addressing unmet health needs.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
